Loading…
Manufactures generic formulations exported to the US, UK and Australia through owned subsidiaries.
Manufactures generic formulations exported to the US, UK and Australia through owned subsidiaries.
Makes the drugs in its own plants and sells them through its own marketing subsidiaries in each regulated market, so it deals directly with pharmacy chains and distributors rather than through a third-party marketer. India is the production base, and sales are mostly overseas.
In one line: A generics manufacturer exporting via owned distribution subsidiaries.
Moat: narrow (regulatory licence). FDA/MHRA-approved plants plus owned marketing subsidiaries in regulated markets support steady exports.
Headquarters: Mumbai, India · Founded: 1982 · Employees: 1,685
Size Marksans Pharma (MARKSANS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.45B, the 480th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹303.70 on 6 Nov 2026.
Performance Over six months the shares gained 49.6%, against -22.7% for the median peer and 0.0% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 24.2% over the last twelve months (peer median +8.0%); the operating margin is 20.0% (peer median -15.6%).
Valuation It trades at 24.2× forward earnings against a peer median of 27.5× (5th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.4 points below its cost of capital (18.9% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹33.9B | ₹29.5B | ₹26.2B | ₹21.8B | ₹18.5B |
| Revenue growth | — | +13% | +20% | +18% | — |
| Gross profit | ₹13.9B | ₹9.45B | ₹8.65B | ₹7.02B | ₹5.96B |
| EBITDA | ₹7.83B | ₹6.00B | ₹5.30B | ₹4.61B | ₹3.52B |
| Net income | ₹5.60B | ₹4.18B | ₹3.81B | ₹3.14B | ₹2.66B |
| Free cash flow | n/a | ₹3.51B | ₹652M | ₹473M | ₹1.88B |
| Capital expenditure | n/a | ₹1.31B | ₹1.73B | ₹2.09B | ₹536M |
| Total debt | ₹4.65B | ₹3.43B | ₹3.22B | ₹2.44B | ₹1.23B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Marksans Pharma MARKSANS.NS | $1.45B | +50% | +24% | 20% | 24.2× | 31.6% |
| Aurobindo Pharma AUROPHARMA.NS | $10.9B | +22% | +14% | 15% | 22.4× | 21.0% |
| Caplin Point Laboratories CAPLIPOINT.NS | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% |
| Lupin LUPIN.NS | $9.65B | -19% | +24% | 24% | 20.9× | 8.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MARKSANS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.7% | -0.4% | 9th lowest of 21 |
| 6-month return | +49.6% | -22.7% | 3rd highest of 21 |
| Distance from 52-week high | -13.5% | -42.6% | 4th highest of 21 |
| Revenue growth (TTM) | +24.2% | +8.0% | 5th highest of 19 |
| Operating margin | 20.0% | -15.6% | 2nd highest of 19 |
| Forward P/E | 24.2× | 27.5× | 5th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 31.6% | 3.2% | 2nd most demanding of 7 |
| Growth delivered (Del g) | +16.6% | +5.8% | 2nd highest of 7 |
| Hurdle (Req g minus delivered) | +15.0 pp | -6.4 pp | 2nd most demanding of 7 |
| ROIC minus cost of capital | -0.4 pp | -8.1 pp | 5th highest of 18 |
| EV / EBITDA | 16.7× | 14.3× | 3rd most expensive of 6 |
| Net debt / EBITDA | -0.8× | -1.5× | 3rd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 24.2× | 31.6% | +16.6% |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 11.8× | 14.9% | +11.1% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | n/a | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | n/a | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 7.7× | -17.5% | +7.0% |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | n/a | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | n/a | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 13.0× | -8.5% | +4.6% |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 585.0× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 45.8× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 71.6× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | n/a | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 42.9× | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 9.4× | -15.4% | +3.9% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | n/a | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | n/a | 49.9% | -13.2% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% | +29.4% |